HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


California biomonitoring bill

This article was originally published in The Rose Sheet

Executive Summary

"The Healthy Californians Biomonitoring Program," which would assess annual fees from manufacturers of cosmetics and personal care products containing triclosan, isopropyl alcohol and other ingredients, will be addressed by the California State Senate Environmental Quality Committee April 19. Introduced Feb. 3 by Sen. Deborah Ortiz (D-Sacramento), SB 1168 would establish a fee system for companies that are "responsible for identifiable sources of toxic chemicals" as a means to support a statewide biomonitoring initiative (1"The Rose Sheet" March 8, 2004, p. 4). The bill is scheduled to be addressed by the Appropriations Committee this month, with floor action slated for May, according to the Breast Cancer Fund, a co-sponsor of the bill. In addition to triclosan and isopropyl alcohol, diethyl phthalate metabolites and lindane, an Rx pediculicide, are included on the list of "toxic" chemicals...

You may also be interested in...

California Biomonitoring Bill Seeks Fees From Companies Using Triclosan

Manufacturers of cosmetics and personal care products containing triclosan, isopropyl alcohol and other ingredients may be assessed annual fees under legislation currently pending in the California state senate, which categorizes the ingredients as toxic chemicals

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts